Cyclerion Partners with Medsteer to Advance Depression Treatment
Cyclerion Therapeutics teams up with Medsteer to develop CYC-126, an innovative therapy for treatment-resistant depression, with Phase 2 trials starting in 2026.
/ 1 item
#CYCN↓